首页> 美国卫生研究院文献>other >Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA
【2h】

Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA

机译:在DNA-PKCS特异性ShRNA通过DNA-PKCS癌症瘤中介导的病毒介导的肿瘤辐射敏化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

One of the key issues in cancer radiotherapy research is to sensitize tumor cells to the cell killing effects of ionizing radiation while leaving normal tissues intact. One potential approach to achieve this is through tumor-specific targeting of DNA repair genes. In this study, we engineered a replication-deficient adenovirus encoding a mini shRNA gene targeted to the DNA-PKcs gene, which is involved in double strand break DNA repair, and evaluated its anti-tumor efficacy in combination with radiotherapy. Our shRNA-encoding adenovirus showed significant efficacy in down-regulating the levels of the DNA-PKcs protein that was accompanied by increased radiation sensitivity in the human HCT116 colon cancer cells. However, when delivered intratumorally to xenograft human tumors, minimal anti-tumor effects of the virus were seen either alone or in combination with radiation therapy, suggesting an inefficiency of the non-replicative adenovirus in delivering shRNA genes to the tumor mass. When a conditionally replicative adenovirus targeted to telomerase-positive tumor cells was used in conjunction with the DNA-PKcs-targeted shRNA-encoding non-replicative adenovirus, the efficiency of tumor-specific anti-DNA-PKcs shRNA gene expression was enhanced significantly. Most importantly, this enhanced shRNA expression led to significant anti-tumor efficacy of concurrently delivered radiation therapy. Our results suggest our shRNA-based DNA-PKcs- targeting approach in combination with tumor-targeting replicative adenovirus is a promising method to sensitize solid tumors to radiation therapy.
机译:癌症放射治疗研究中的关键问题之一是使肿瘤细胞敏感到电离辐射的细胞杀伤作用,同时留下正常组织完整。实现这一目标的一种潜在方法是通过DNA修复基因的肿瘤特异性靶向。在这项研究中,我们设计了一种复制缺陷的腺病毒,其编码靶向DNA-PKCS基因的迷你shRNA基因,其参与双链断裂DNA修复,并与放射疗法组合评估其抗肿瘤效果。我们的shRNA编码的腺病毒显示出对下调DNA-PKCS蛋白水平的显着功效,所述DNA-PKCS蛋白的水平伴随着人HCT116结肠癌细胞中的辐射敏感性增加。然而,当涉及异种移植人肿瘤的涉及妥协时,病毒的最小抗肿瘤效应单独或与放射治疗组合,表明非重复腺病毒在将shRNA基因递送到肿瘤质量的效率。当与DNA-PKCS靶向的非重复性腺病毒结合使用靶向端粒酶阳性肿瘤细胞的有条件的复制腺病毒时,肿瘤特异性抗DNA-PKCS SHRNA基因表达的效率显着提高。最重要的是,这种增强的shRNA表达导致同时递送的放射治疗的显着抗肿瘤疗效。我们的研究结果表明,基于shRNA的DNA-PKCS-靶向方法与肿瘤靶向复制腺病毒组合是一种有希望敏化固体肿瘤与放射治疗的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号